Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14917222 | 1.00 | GRM4 (0.45) | GRM4GSK3BGRM5EGFRERBB2 | |
| SCHEMBL14916628 | 0.99 | GRM4 (0.46) | GRM4GSK3BGRM5EGFRERBB2 | |
| SCHEMBL14916629 | 0.99 | GRM4 (0.46) | GRM4GSK3BGRM5EGFRERBB2 | |
| SCHEMBL10065055 | 0.95 | GSK3B (0.45) | GRM4GSK3BGRM5KDRKDM4E | |
| SCHEMBL14917388 | 0.95 | GSK3B (0.45) | GRM4GSK3BGRM5KDRKDM4E | |
| SCHEMBL14917140 | 0.82 | P2RX7 (0.38) | GRM4KDM4ECES1ALDH1A1POLB | |
| SCHEMBL14917141 | 0.82 | P2RX7 (0.38) | GRM4KDM4ECES1ALDH1A1POLB | |
| SCHEMBL14916973 | 0.81 | MAPT (0.45) | GAAKDM4ESMYD3SMN1; SMN2ALDH1A1 | |
| SCHEMBL10065512 | 0.81 | MAPT (0.45) | GAAKDM4ESMYD3SMN1; SMN2ALDH1A1 | |
| SCHEMBL14916838 | 0.76 | CTSS (0.36) | SMN1; SMN2NPC1RAB9APOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116445-A1 | TRIAZOLIUM CARBENE CATALYSTS AND PROCESSES FOR ASYMMETRIC CARBON-CARBON BOND FORMATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116445-A1 | TRIAZOLIUM CARBENE CATALYSTS AND PROCESSES FOR ASYMMETRIC CARBON-CARBON BOND FORMATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116445-A1 | TRIAZOLIUM CARBENE CATALYSTS AND PROCESSES FOR ASYMMETRIC CARBON-CARBON BOND FORMATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2012009372-A2 | TRIAZOLIUM CARBENE CATALYSTS AND PROCESSES FOR ASYMMETRIC CARBON-CARBON BOND FORMATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116445-A1 | TRIAZOLIUM CARBENE CATALYSTS AND PROCESSES FOR ASYMMETRIC CARBON-CARBON BOND FORMATION | TIMCC, CYCS, CTRC | GRM4 3580/4885GSK3B 910/4885GRM5 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.